Novo Nordisk Faces Twin Tests: Unverified Data Leak Claims and a Valuation Bet on Wegovy's Pill

Novo Nordisk finds itself navigating two unrelated uncertainties at once — a set of unconfirmed allegations about how it tracks healthcare professionals, and a debate over whether its shares are cheap enough to buy. Neither question has a settled answer, and investors are left weighing claims that the company has not verified against demand figures that are concrete.

Leaked Documents, Unconfirmed Content

This week's focus on Novo's handling of information about medical staff stems from a report by Ingeniøren. According to that outlet, internal documents rank physicians and nurses by commercial potential and loyalty. The reported figures: 7,389 doctors and nurses assessed, more than 2,600 given the company's highest rating, and material covering 46,843 healthcare professionals in total.

Those numbers describe what the documents are alleged to contain — not an established fact. Novo Nordisk has not confirmed them and cautions that the material may have been altered or falsified. The company's explicit refusal to authenticate the records limits how much weight the allegations can carry. From the reporting alone, neither the authenticity of the datasets nor their actual use by Novo can be inferred.

The hacker group FulcrumSec claimed in June to have had access to Novo's systems for several months and demanded USD 25 million; Novo rejected the demand. The group also asserted it had obtained the formula for Amycretin. That claim, too, must be kept distinct from a proven loss of confidential research information. Novo's warning about potentially manipulated material bears on the reliability of the published documents — it does not establish that the alleged formula actually leaked.

AI Research Push Adds a Separate Data Angle

Alongside the leak story, Novo is leaning on digital tools in drug discovery. A report yesterday described its use of OpenAI's Rosalind model, with applications said to include identifying targets, designing molecules and evaluating clinical trials. OpenAI has also acquired Orchestra Bio to expand Rosalind's life-sciences capabilities. What practical benefit Novo derives for its pipeline, research timelines or efficiency remains open — and no link between this AI work and the claimed data breaches has been established.

The Bull Case: A Multiple of 14 Against Lilly's 34

Separately, columnist Eric Fry came out in favor of Novo Nordisk as an investment yesterday. His thesis pairs a comparatively low valuation with the success of the Wegovy pill. He points to a price-to-earnings ratio of roughly 14 for Novo versus 34 for Eli Lilly, and considers a doubling of the stock possible — though he stresses it is not guaranteed.

A low multiple on its own does not answer the key investor question. It can be an opportunity if business trends stabilize; if earnings expectations keep sliding, the discount says less. The success of new products therefore has to show up in results. On that front the picture is muted: Zacks consensus estimates point to Novo's revenue falling about 3% in 2026 versus the prior year, with earnings per share expected to decline around 14%.

Five Million Prescriptions Behind the Optimism

Fry's positive view rests on roughly 5 million US prescriptions for the Wegovy pill in the first six months — by his account about 76% of the US oral obesity market. That demand is the most tangible part of his case: it shows Novo is already reaching patients with the tablet. Prescription counts, however, are not direct proof that group profit will rise.

CagriSema remains an additional test. Novo holds to its view that the drug matters for earnings growth in the years ahead, while analysts stay skeptical. One analyst expects a particularly rapid US launch after a possible approval. The FDA decision is anticipated in the fourth quarter of 2026, with Novo expecting a market launch in early 2027. That expectation is distinct from an approval already granted: CagriSema is not yet cleared in the US.

For the stock, then, two different kinds of uncertainty sit side by side. The benefit of the AI tools has yet to prove itself, while the published data allegations remain unconfirmed. Neither a measurable research advantage nor a concrete economic damage can so far be treated as a reliable basis for valuation. Fry's case rests on a cheap multiple and demonstrable Wegovy demand; a lasting re-rating would need a more convincing earnings outlook to emerge from them. The tablet's success supports that hope — the declining consensus estimates currently cap its force.